Chemical Combination and Method for Increasing Delivery of Coenzyme Q10

• US 20110318405A1
• Filed: 08/22/2011
• Published: 12/29/2011
• Est. Priority Date: 06/25/2003
• Status: Abandoned Application

• Current Assignee: Charles Erwin
• Original Assignee: Charles Erwin
• Inventors: Erwin, Charles
• Application Number:
  US13/215,114
• Publication Number:
  US 20110318405A1
• Time in Patent Office: Days
• US Class Current: 424/448
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006

Abstract

The present invention relates to a chemical combination and method for increasing delivery of Coenzyme Q10. The chemical combination comprises Coenzyme Q10 mixed with at least one chemical. The at least one chemical includes cyclic terpene containing essential oil(s) that permit unprecedented levels of Coenzyme Q10 to be made available for delivery and absorption, increasing bioavailability, as well as overcoming the previous limits. A transdermal patch including a layer containing Coenzyme Q10 is also provided.

Claims

1. A transdermal patch comprising:

an adhesive layer; and

a composition comprising;

co-enzyme Q10; and

a solvent.

2. The transdermal patch of claim 1 further comprising a first skin buffer, a first anti-oxidant, a second skin buffer, and a second anti-oxidant.

3. The transdermal patch of claim 2 wherein

the coenzyme Q10 is present in an amount from 5 to 30 percent by weight of the total weight of the composition;

the solvent is present in an amount from 30 to 85 percent by weight of the total weight of the composition wherein the solvent is selected from the group consisting of cetyl myristoleate, dimethyl sulfoxide, d-limonene, the essential oil lavindin, the essential oils of peppermint, ginger, camphor, geranium, orange, tea tree, lavender, cyclic terpenes containing essential oils, and mixtures thereof;

the first skin buffer is present in an amount from 1 to 25 percent by weight of the total weight of the composition wherein the first skin buffer is selected from the group consisting of dl-alpha Tocopheryol acetate, cetyl myristoleate, gamma linolenic acid, conjugated linolenic acid, d-alpha Tocopherol, lecithin, lidocaine, and mixtures thereof;

the first anti-oxidant is present in an amount from 1 to 10 percent by weight of the total weight of the composition;

the second skin buffer is present in an amount from 1 to 20 percent by weight of the total weight of the composition; and

the second anti-oxidant is present in an amount of 1 to 5 percent by weight of the total weight of the composition.

4. The transdermal patch of claim 2 wherein the second skin buffer is selected from the group consisting of dl-alpha Tocopheryol acetate, cetyl myristoleate, gamma linolenic acid, conjugated linoleic acid, d-alpha Tocopherol, lecithin, lidocaine, and mixtures thereof.

5. The transdermal patch of claim 2 wherein the solvent is d-limonene.

6. The transdermal patch of claim 2 wherein the first skin buffer is cetyl myristoleate and the second skin buffer is dl-alpha Tocopheryol acetate.

7. The transdermal patch of claim 2 wherein the first anti-oxidant is alpha lipoic acid and the second anti-oxidant is d-alpha Tocopheryol Succinate.

8. The transdermal patch of claim 2 wherein the first and second anti-oxidants are independently selected from the group consisting of alpha lipoic acid;

d-alpha Tocopheryol Succinate;

Vinpocetin;

Ergoloid Mesylates; and

Vitamin(s) A(s), C(s), D(s), E(s), and K(s); and

mixtures thereof.

9. The transdermal patch of claim 1 wherein the composition comprises a fraction selected from the group consisting of a D Limonene fraction, a DMSO soluble fraction, an ethyl alcohol fraction, and combinations thereof.

10. A transdermal patch comprising:

an adhesive layer; and

a composition comprising;

co-enzyme Q10;

a solvent; and

a component selected from the group consisting of antioxidants, vitamins, steroids, melatonin, minerals, muscle relaxants, anti-inflammatory compounds, and combinations thereof.

11. The transdermal patch of claim 10 wherein the transdermal composition includes alpha lipoic acid in an amount from about 10 to 90% of the total weight of the transdermal composition.

12. The transdermal patch of claim 11 wherein the transdermal composition includes ascorbyl palmitate in an amount from about 0.0001 to about 0.003% of the total weight of the transdermal composition.

13. The transdermal patch of claim 12 wherein the transdermal composition includes ergoloid mesylates typically in an amount from about 0.01 to about 1% of the total weight of the transdermal composition.

14. The transdermal patch of claim 13 wherein the transdermal composition includes cyanocobalamine and methylcobalamine.

15. The transdermal patch of claim 14 wherein the transdermal composition includes a component selected from pregnenolone, testosterone, progesterone, 5-alpha hydroxy Laxogenin, antrostenodione, androstenodiol, and combinations thereof.

16. The transdermal patch of claim 15 wherein the transdermal composition includes a component selected from the group consisting of DHEA, strontium chloride hexahydrate, magnesium chloride hexahydrate, lobelia seed extract and combinations thereof.